On the 31 March 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,670 million and NAV per share was SEK 41.90. Return on NAV per share in the month was -1.09%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Lipum | 100% | 348 | 3.97 | 9.5% |
| Prokarium | 50% | 281 | 3.21 | 7.7% |
| Xspray Pharma | 18% | 225 | 2.57 | 6.1% |
| Empros Pharma | 79% | 204 | 2.33 | 5.6% |
| KAHR Medical | 34% | 204 | 2.33 | 5.6% |
| Atrogi | 44% | 197 | 2.25 | 5.4% |
| Bonsai Biotherapeutics | 100% | 158 | 1.80 | 4.3% |
| Xintela | 60% | 128 | 1.46 | 3.5% |
| Microbiotica | 10% | 126 | 1.44 | 3.4% |
| AnaCardio | 13% | 79 | 0.91 | 2.2% |
| Geneos Therapeutics | 12% | 68 | 0.78 | 1.9% |
| Mendus | 23% | 62 | 0.70 | 1.7% |
| EpiEndo Pharmaceuticals | 9% | 54 | 0.62 | 1.5% |
| Vitara Biomedical | 11% | 54 | 0.61 | 1.5% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.36 | 0.9% |
| Egetis Therapeutics | 1% | 27 | 0.31 | 0.7% |
| Amarna Therapeutics | 58% | 11 | 0.13 | 0.3% |
| Strike Pharma | 18% | 11 | 0.12 | 0.3% |
| Alder Therapeutics | 30% | 0 | 0.00 | 0.0% |
| Total | 2,269 | 25.90 | 61.8% | |
| Commercial Growth | ||||
| Symcel | 30% | 204 | 2.33 | 5.6% |
| NorthX Biologics | 61% | 202 | 2.30 | 5.5% |
| Chromafora | 28% | 137 | 1.57 | 3.7% |
| Nanologica | 50% | 59 | 0.68 | 1.6% |
| Frontier Biosolutions | 2% | 26 | 0.30 | 0.7% |
| Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
| Total | 630 | 7.19 | 17.2% | |
| Assets related to Portfolio companies | 183 | 2.08 | 5.0% | |
| Other assets and liabilities | 589 | 6.73 | 16.1% | |
| Net Asset Value | 3,670 | 41.90 | 100.0% | |